Publications by authors named "Serena Di Cosimo"

100Publications

Advancing immunotherapy for early-stage triple-negative breast cancer.

Authors:
Serena Di Cosimo

Lancet 2020 10 20;396(10257):1046-1048. Epub 2020 Sep 20.

Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20100, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(20)31962-0DOI Listing
October 2020

Commentary: SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China.

Front Oncol 2020 10;10:1223. Epub 2020 Jul 10.

Clinical Epidemiology and Trial Organization Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2020.01223DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365943PMC
July 2020

Automated breast ultrasound compared to hand-held ultrasound in surveillance after breast-conserving surgery.

Tumori 2020 Jun 18:300891620930278. Epub 2020 Jun 18.

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0300891620930278DOI Listing
June 2020

Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019.

Eur J Cancer 2020 08 4;135:62-65. Epub 2020 Jun 4.

Medica Scientia Innovation Research (MedSIR), Ridgewood, NJ, USA and Barcelona, Spain; IOB Institute of Oncology, Quironsalud Group, Madrid and Barcelona, Spain; Vall D´Hebron Institute of Oncology (VHIO), Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2020.05.026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7269953PMC
August 2020

Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity before and after Neoadjuvant Chemotherapy.

Cancers (Basel) 2019 Nov 8;11(11). Epub 2019 Nov 8.

Biomarker Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Via Giovanni Antonio Amadeo 42, 20133 Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11111753DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6895966PMC
November 2019

The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells.

Semin Cancer Biol 2020 02 15;60:344-350. Epub 2019 Oct 15.

Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semcancer.2019.10.008DOI Listing
February 2020

Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit.

Br J Cancer 2018 12 27;119(12):1487-1494. Epub 2018 Nov 27.

Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-018-0318-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6288086PMC
December 2018

How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case.

Semin Cancer Biol 2017 06 22;44:106-116. Epub 2017 Apr 22.

Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G.A. Amadeo, 42, 20133 Milan, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semcancer.2017.04.007DOI Listing
June 2017

Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.

J Clin Oncol 2017 May 13;35(13):1421-1429. Epub 2017 Mar 13.

Amir Sonnenblick, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Dominique Agbor-Tarh and Ian Bradbury, Frontier Science, Kingussie, United Kingdom; Serena Di Cosimo Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy; Hatem A. Azim Jr, Martine Piccart-Gebhart and Evandro de Azambuja, Université Libre de Bruxelles; Debora Fumagalli, Breast International Group, Brussels, Belgium; Severine Sarp, Novartis Pharma AG, Basel, Switzerland; Antonio C. Wolff, Johns Hopkins School of Medicine, Baltimore, MD; Lyndsay Harris, Case Western Reserve University School of Medicine, Cleveland, OH; Julie Gralow, Seattle Cancer Care Alliance, Seattle, WA; Alvaro Moreno-Aspitia, Mayo Clinic, Jacksonville, FL; Michael Andersson, Rigshospitalet University Hospital Copenhagen, Denmark; Judith Kroep, Leiden University Medical Center, Leiden, the Netherlands; Tanja Cufer, University Clinic Golnik Medical Faculty, Ljubljana, Slovenia; Sergio D. Simon, Hospital Israelita Albert Einstein; Sergio D. Simon, Grupo Brasileiro de Estudos do Cancer de Mama, São Paulo, Brazil; Pamela Salman, Fundación Arturo López Pérez, Santiago, Chile; Masakazu Toi, Kyoto University, Kyoto, Japan; Maccon Keane, University Hospital Galway, Galway; and Maccon Keane, Cancer Trials Ireland, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.7722DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455460PMC
May 2017

Disease-free interval in metastatic breast cancer patients undergoing complete remission: implications of cross-sectional study design and biologic considerations about disease history.

Breast Cancer 2017 05 6;24(3):491-492. Epub 2017 Mar 6.

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, via G. Venezian 1, 20133, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12282-017-0766-zDOI Listing
May 2017

HER2-Positive Neuroendocrine Breast Cancer: Case Report and Review of Literature.

Breast Care (Basel) 2016 Dec 9;11(6):424-426. Epub 2016 Dec 9.

Department of Medical Oncology, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000453572DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5290429PMC
December 2016

Complete remission in metastatic breast cancer: expecting the unexpected-results of a cross-sectional study.

Breast Cancer 2017 Jul 5;24(4):635-641. Epub 2017 Jan 5.

Division of Medical Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, via G. Venezian 1, 20133, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12282-017-0751-6DOI Listing
July 2017

Platinum salts in advanced breast cancer: a systematic review and meta-analysis of randomized clinical trials.

Breast Cancer Res Treat 2016 12 21;160(3):425-437. Epub 2016 Oct 21.

Division of Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-016-4025-3DOI Listing
December 2016

Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts.

Oncotarget 2016 10;7(42):67956-67965

Breast Surgical Unit, Breast Cancer Center, Hospital Universitario Vall d´Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.11815DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356531PMC
October 2016

Vinorelbine With Capecitabine, an Evergreen Doublet for Advanced Breast Cancer: A Systematic Literature Review and Pooled-Analysis of Phase II-III Studies.

Clin Breast Cancer 2016 10 13;16(5):327-334. Epub 2016 May 13.

Department of Oncology, Medical Oncology Unit, Azienda Ospedaliera Treviglio, Treviglio, Bergamo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2016.05.002DOI Listing
October 2016

Waiting for Godot: Predictive factors for adjuvant treatment of patients with luminal breast cancer.

Breast 2016 Jun 23;27:187-8. Epub 2016 Apr 23.

Laboratory of Methodology for Clinical Research, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2016.02.002DOI Listing
June 2016

Better Together: Targeted Combination Therapies in Breast Cancer.

Semin Oncol 2015 Dec 24;42(6):887-95. Epub 2015 Sep 24.

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2015.09.029DOI Listing
December 2015

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.

J Clin Oncol 2016 Apr 23;34(10):1034-42. Epub 2015 Nov 23.

Martine Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Eileen Holmes, Eleanor McFadden, and Andrew P. Holmes, Frontier Science (Scotland), Kincraig, Kingussie, United Kingdom; José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium; Evandro de Azambuja and Stella Dolci, Breast European Adjuvant Study Team, Brussels, Belgium; Amylou C. Dueck and Anne E. McCullough, Mayo Clinic, Scottsdale, AZ; Giuseppe Viale, University of Milan, Milan, Italy; Giuseppe Viale and Aron Goldhirsch, Istituto Europeo di Oncologia, Milan, Italy; Jo Anne Zujewski, National Cancer Institute, Bethesda, MD; Aron Goldhirsch, Ospedale Regionale di Lugano, Viganello-Lugano, Switzerland; Alison Armour, GlaxoSmithKline, Collegeville, PA; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada; Kathleen I. Pritchard, University of Toronto, Toronto, Ontario, Canada; Liu Tonghua, Peking Union Medical College Hospital, Beijing, People's Republic of China; Liu Tonghua and Binghe Xu, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Phuong Dinh, Breast International Group, Brussels, Belgium; Serena Di Cosimo, Istituto Nazionale del Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Nadia Harbeck, Frauenklinik der Universität München, Munich, Germany; Sergei Tjulandin, Blokhin Russian Cancer Research Center of RAMS, Moscow, Russia; Young-Hyuck Im, Korean Cancer Study Group, Seoul, South Korea; Young-Hyuck Im, Samsung Medical Center, Seoul, South Korea; Chiun-Shen Huang, National Taiwan University Hospital, Taipei, Republic of China; Véronique Diéras, Institut Curie, Paris, France; David W. Hillman, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Christian Jackisch, Klinikum Offenba

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.1797DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872016PMC
April 2016

Trastuzumab cardiac toxicity: a problem we put our heart into.

Tumori 2016 Jan-Feb;102(1):1-5. Epub 2015 Jul 30.

Department of Medical Oncology, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan - Italy.

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/full/10.5301/tj.5000393
Publisher Site
http://dx.doi.org/10.5301/tj.5000393DOI Listing
July 2016

Did circulating tumor cells tell us all they could? The missed circulating tumor cell message in breast cancer.

Int J Biol Markers 2015 Nov 11;30(4):e429-33. Epub 2015 Nov 11.

Biomarkers Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan - Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5301/jbm.5000166DOI Listing
November 2015

International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013).

J Natl Cancer Inst Monogr 2015 May;2015(51):90-6

Medical Oncology Unit (VA, ABe), University of Brescia, and Breast Unit (RP, LV, ELS) Spedali Civili Hospital, Brescia, Italy; U.O. Multidisciplinare di Patologia Mammaria, S.S. Terapia Molecolare e Farmacogenomica, AZ. Istituti Ospitalieri di Cremona, Cremona, Italy (DG, AR, MRC, LD, ABo); Departments of Radiation Oncology (TB) and Pathology (FS), University of Texas MD Anderson Cancer Center, Houston, TX; Department of Medical Oncology and Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA (MC); Division of Experimental Therapeutics, Breast Cancer Program, Istituto Europeo di Oncologia, Milan, Italy (GC); Biomarkers Unit, Department of Experimental Oncology and Molecular Medicine (MGD), and Medical Oncology Unit (SDC), Fondazione IRCCS - Istituto Nazionale Tumori, Milan, Italy (MGD); Academic Department of Biochemistry, Biochemical Endocrinology (MD), Department of Surgery, Breast Unit (PB), and The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research and Breast Unit (MD, GS), Royal Marsden Hospital, London, UK; Department of Pathology, Melbourne University, Parkville, Australia (SF); Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK (ALH); Mount Vernon Cancer Centre, London, UK (AM); Section of Medical Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT (CH); Memorial Sloan Kettering Cancer Center, New York, NY (CAH); Division of Medical Oncology, Department of Hemato-oncology, IRCCS Policlinico 'San Matteo' Foundation, Pavia, Italy (PP); Dipartimento Medicina di Laboratorio, SC Anatomia ed Istocitopatologia Diagnostica e di Screening, A.O.U. Città della Salute e della Scienza di Torino, Università di Torino, Turin, Italy (AS); N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia (VS); German Breast Group & University of Frankfurt, Neu-Isenburg, Germany (GvM); The Russell H. Morgan Department of Radiology

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jncimonographs/lgv023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009414PMC
May 2015

Prognosis of women with early breast cancer and PIK3CA mutations.

Breast 2015 Jun 12;24(3):283-4. Epub 2015 Mar 12.

Department of Oncology, Istituto Nazionale dei Tumori, Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2015.02.028DOI Listing
June 2015

Pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy.

Breast 2014 Oct 28;23(5):690-1. Epub 2014 Jun 28.

Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Venezian 1, 20133 Milano, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2014.06.007DOI Listing
October 2014

Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients.

Pharmgenomics Pers Med 2013 Dec 16;7:1-19. Epub 2013 Dec 16.

Division of Medical Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/PGPM.S53304DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3883531PMC
December 2013

Neoadjuvant treatment of HER2 and hormone-receptor positive breast cancer - moving beyond pathological complete response.

Breast 2014 Apr 4;23(2):188-92. Epub 2014 Jan 4.

U.O. Multidisciplinare di Patologia Mammaria/U.S. Terapia Molecolare e Farmacogenomica, AZ. Istituti Ospitalieri di Cremona, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2013.12.005DOI Listing
April 2014

microRNAs in breast cancer development and treatment.

Cancer Treat Rev 2014 Jun 14;40(5):595-604. Epub 2013 Nov 14.

Department of Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Via Giacomo Venezian 1, 20133 Milan, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2013.11.002DOI Listing
June 2014

Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial.

J Clin Oncol 2013 12 18;31(36):4504-11. Epub 2013 Nov 18.

Jose Baselga, Memorial Sloan-Kettering Cancer Center, NY; James G. Greger Jr, GlaxoSmithKline, Collegeville, PA; Hatem A. Azim Jr, Martine Piccart, Evandro de Azambuja, BrEAST Data Centre, Institut Jules Bordet, Université Libre de Bruxelles; Phuong Dinh, Breast International Group, Brussels; Peter Vuylsteke, Sint-Elisabeth Hospital, Namur, Belgium; Dominique Agbor-tarh, Ian Bradbury, Frontier Science, Kincraig, Kingussie, Scotland; Ian Smith, Royal Marsden Hospital, and Institute of Cancer Research, London, United Kingdom; Serena Di Cosimo, IRCCS Fondazione Instituto Nazionale dei Tumori, Milan, Italy; Serena Di Cosimo, SOLTI Breast Cancer Research Group, Barcelona, Spain; Christian Jackisch, Kilinikum Offenbach, Offenbach; Bahriye Aktas, Kliniken Essen-Mitte, Evang, Essen; Holger Eidtmann, University Hospital Kiel, Kiel, Germany; Sung-Bae Kim, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; Chiun-Sheng Huang, National Taiwan University Hospital; Ruey Kuen Hsieh, Mackey Memorial Hospital, Taipei, Taiwan; and Lydia Dreosti, University of Pretoria, Pretoria, South Africa.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.50.9448DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5795667PMC
December 2013

Re: time to adjuvant chemotherapy for breast cancer in national comprehensive cancer network institutions.

J Natl Cancer Inst 2013 Dec 11;105(24):1912. Epub 2013 Nov 11.

Affiliations of authors: Department of Oncology, IRCCS Fondazione Istituto Nazionale dei Tumori, Milano, Italy (SDC); Department of Oncology (LdM, JC), and Beast Cancer Surgery (IR), Vall d'Hebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djt324DOI Listing
December 2013

Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-study from the NeoALTTO phase III trial.

Breast 2013 Dec 20;22(6):1060-5. Epub 2013 Sep 20.

Breast Cancer Translational Research Laboratory, J.C. Heuson, Université Libre de Bruxelles, Institut Jules Bordet, Brussels, Belgium; Department of Medicine, BrEAST Data Centre, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2013.08.014DOI Listing
December 2013

Implication of breast cancer phenotype for patients with leptomeningeal carcinomatosis.

Breast 2013 Feb 6;22(1):19-23. Epub 2012 Nov 6.

Breast Cancer Center, Vall d'Hebron University Hospital, Passeig de la Vall d'Hebron 119-129, 08035 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2012.10.009DOI Listing
February 2013

Brain metastases in HER2-positive breast cancer: challenges and opportunities.

Ann Palliat Med 2012 Oct;1(3):195-7

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2224-5820.2012.10.11DOI Listing
October 2012

Heart to heart with trastuzumab: a review on cardiac toxicity.

Authors:
Serena Di Cosimo

Target Oncol 2011 Dec 29;6(4):189-95. Epub 2011 Nov 29.

Breast Cancer Center, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-011-0203-8DOI Listing
December 2011

Management of breast cancer with targeted agents: importance of heterogeneity. [corrected].

Nat Rev Clin Oncol 2010 Mar 2;7(3):139-47. Epub 2010 Feb 2.

Breast Cancer Center, Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, 08035 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrclinonc.2009.234
Publisher Site
http://dx.doi.org/10.1038/nrclinonc.2009.234DOI Listing
March 2010

Controversies in breast cancer: the mammalian target of rapamycin as a target for breast cancer therapy.

Authors:
Serena Di Cosimo

Breast Cancer Res 2009 18;11 Suppl 3:S25. Epub 2009 Dec 18.

Breast Cancer Centre, Vall d-Hebron University Hospital, Passeig Vall d-Hebron 119-129, 08305 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/bcr2444DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2797705PMC
May 2010

Phosphoinositide 3-kinase mutations in breast cancer: a "good" activating mutation?

Clin Cancer Res 2009 Aug 11;15(16):5017-9. Epub 2009 Aug 11.

Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-1173DOI Listing
August 2009

Targeted therapies in breast cancer: where are we now?

Eur J Cancer 2008 Dec 14;44(18):2781-90. Epub 2008 Nov 14.

Medical Oncology Program, Medical Oncology Department, Vall d'Hebron University Hospital, Passeig Vall d'Hebron, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2008.09.026DOI Listing
December 2008

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

J Natl Cancer Inst 2007 Apr;99(8):628-38

Medical Oncology Program, Medical Oncology Department, Vall d'Hebron University Hospital and Research Institute, Barcelona 08035, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djk134DOI Listing
April 2007

Is anthracycline-based chemotherapy alone adequate for young women with estrogen receptor-positive breast cancer?

Breast 2006 Apr 29;15(2):269-72. Epub 2005 Aug 29.

Division of Medical Oncology A, Regina Elena Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S096097760500134
Publisher Site
http://dx.doi.org/10.1016/j.breast.2005.05.007DOI Listing
April 2006

Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma.

Cancer 2004 Jul;101(1):133-8

Divisions of Medical Oncology "A" and "C", Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.20338DOI Listing
July 2004

A man with a deltoid swelling and paraneoplastic erythrocytosis: case report.

Anticancer Res 2003 Nov-Dec;23(6D):5181-4

Department of Oncology, University of Rome La Sapienza, San Andrea Hospital, Via E. Chianesi 53, 00128 Rome, Italy.

View Article

Download full-text PDF

Source
April 2004

Breast cancer metastatic to the choroid in a male patient: case report.

Tumori 2003 May-Jun;89(3):333-5

Operative Unit of Medical Oncology, Oncology Center Giorgio Porfiri, Hospital Santa Maria Goretti, Latina, Italy.

View Article

Download full-text PDF

Source
September 2003

Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors.

Drugs Today (Barc) 2003 Mar;39(3):157-74

Department of Medical Oncology, University La Sapienza, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1358/dot.2003.39.3.799451DOI Listing
March 2003

Gastric stump lymphoma five years after distal gastrectomy.

Leuk Lymphoma 2003 Feb;44(2):365-7

Department of Medical Oncology, University La Sapienza, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1042819021000050034DOI Listing
February 2003